4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly losses of $(0.87) per share. This is a 210.71 percent decrease over losses of $(0.28) per share from the same period last year.
Unanimous Support for AstraZeneca and Sanofi’s Nirsevimab: Next Generation RSV Treatment on the Horizon
The FDA's Antimicrobial Drugs Advisory Committee has voted unanimously 21 to 0 that AstraZeneca plc (NASDAQ: AZN) and Sanofi SA's (NASDAQ: SNY) nirsevimab has a favorable benefit-risk profile t